Generic Name and Formulations:
Beclomethasone dipropionate 40mcg, 80mcg; per actuation; non-aqueous nasal spray soln.
Indications for QNASL:
Seasonal and perennial allergic rhinitis.
Adults and Children:
<4yrs: not established. 4–11yrs: 1 spray (40mcg) in each nostril once daily; max: 2 sprays per day. ≥12yrs: 2 sprays (80mcg) in each nostril once daily; max: 4 sprays per day.
Avoid in recent nasal septal ulcers, nasal surgery, or nasal trauma until healed. Monitor periodically for possible changes in nasal mucosa or Candida infection with long-term use. Discontinue if nasal erosion/ulceration or Candida infection occur (treat with local therapy). Change in vision, history of increased intraocular pressure, blurred vision, glaucoma, and/or cataracts: monitor closely. Respiratory tract tuberculosis. Untreated infections (eg, fungal, bacterial, viral, ocular herpes simplex). If exposed to measles or chickenpox, consider anti-infective prophylactic therapy. If adrenal insufficiency exists following systemic corticosteroid therapy, replacement with intranasal corticosteroids may exacerbate symptoms of adrenal insufficiency (eg, lassitude, depression). Monitor for hypercorticism and adrenal suppression (if occur discontinue gradually). Monitor for growth suppression in children. Avoid eyes, mouth and face. Pregnancy (Cat.C). Nursing mothers.
Nasal discomfort, epistaxis, headache, pyrexia, upper respiratory tract infection, nasopharyngitis; hypersensitivity reactions (discontinue if occurs).
Aerosol 40mcg—4.9g (60 actuations), 8.7g (120 actuations); 80mcg—8.7g (120 actuations)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
- Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
- Prostate Cancer Drug Resistance Mediated by Epigenetic Changes
- Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML